Previous issue | Volume 89 | ESPE2018 | Next issue

57th Annual ESPE

Athens, Greece
27 Sep 2018 - 29 Sep 2018

Card image cap
ESPE 2018 57th European Society for Paediatric Endocrinology Annual Meeting 27-29 September 2018 Athens, Greece

Poster Presentations

Bone, Growth Plate & Mineral Metabolism P1

Intrauterine Growth Restriction, Antenatal Steroids, Gestational Age and Breast Feeding Influence Bone Health in Prepubertal Children Born Preterm
aDepartment of Pediatrics, Istituto Giannina Gaslini, University of Genova, Genova, Italy; bGiannina Gaslini Institute, Genova, Italy; cEpidemiology and Biostatistics Section, Scientific Directorate, Istituto Giannina Gaslini, Genova, Italy; dNeonatal Intensive Care Unit Giannina Gaslini Institute, Genova, Italy.
hrp0089p1-p025
Duration of Breastfeeding and Bone Mineral Density in Childhood - A Prospective Study Among Preschool Children
aNational University of Singapore, Singapore, Singapore; bKK Women’s and Children’s Hospital, Singapore, Singapore; cSingapore Institute of Clinical Sciences, A*STAR, Singapore, Singapore; dLiggins Institute, Auckland, New Zealand; eUniversity of Southampton & University Hospital Southampton, Southhampton, UK; fUniversity of Helsinki, Helsinki, Finland; gKhoo Teck Puat–National University Children’s Medical Institute, Singapore, Singapore; hKhoo Teck Puat–National University Children’s Medical Institute, Bethesda, Maryland, UK; iLee Kong Chian School of Medicine, Singapore, Singapore.
hrp0089p1-p026
Bone Health in Adolescents Born Small for Gestational Age (SGA)
aLithuanian University of Health Sciences, Medical Academy, Department of Endocrinology, Kaunas, Lithuania; bLithuanian University of Health Sciences, Medical Academy, Department of Radiology, Kaunas, Lithuania; cUniversity of Gothenburg, The Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Physiology/Endocrinology, Gothenburg, Sweden; dLithuanian University of Health Sciences, Medical Academy, Institute of Endocrinology, Kaunas, Lithuania
hrp0089p1-p027
Longitudinal Study of Bone Mass in Swedish Children Treated with Modified Ketogenic Diet
aDepartment of Pediatrics, The Queen Silvia Children’s Hospital, Gothenburg, Sweden; bInstitution of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; cDepartment of Clinical Chemistry, Linköping University, Linköping, Sweden
hrp0089p1-p028
Fracture Epidemiology for Children in Western Australia between 2005-2015: Do We Need to be Concerned about Bone Health?
aCentre for Exercise and Sports Science Research, Edith Cowan University, Perth, WA, Australia; bWestern Australian Bone Research Collaboration, Perth, WA, Australia; cExercise Medicine Research Institute, Perth, WA, Australia; dInstitute for Health Research, University of Notre Dame Australia, Perth, WA, Australia; eExercise Medicine Research Institute, Edith Cowan University, Perth, WA, Australia; fGerontology Research Center, University of Jyväskylä, Jyväskylä, Finland; gEmergency Department, Princess Margaret Hospital, Perth, WA, Australia; hUniversity of Western Australia, Medical School, Division of Paediatrics, Perth, WA, Australia; iSchool of Health Sciences, University of Notre Dame Australia, Perth, WA, Australia; jDepartment of Orthopaedic Surgery, Princess Margaret Hospital, Perth, WA, Australia; kDepartment of Endocrinology and Diabetes, Princess Margaret Hospital, Perth, WA, Australia; lTelethon Kids Institute for Child Health Research, Perth, WA, Australia
hrp0089p1-p029
Bone Biochemistry in Children with Fractures Presenting with Suspected Non-accidental Injury
aChild Protection Service, Royal Hospital for Chidren, Glasgow, UK; bBiochemistry Department, Royal Hospital for Children, Glasgow, UK; cRoyal Hospital for Children, Glasgow, UK; dDevelopmental Endocrinology Research Group University of Glasgow, Glasgow, UK
hrp0089p1-p030
Systematic Screening Using DXA Lateral Vertebral Morphometry is Associated with a High Prevalence of Vertebral Fractures in Duchenne Muscular Dystrophy: Results from ScOT-DMD Study
aDevelopmental Endocrinology Research Group The Royal Hospital for Children, Glasgow, UK; bPaediatric Neurosciences Research Group, The Royal Hospital for Children, Glasgow, UK; cDevelopmental Endocrinology Research Group, The Royal Hospital for Children, Glasgow, UK; dWest of Scotland Genetic Services, Queen Elizabeth University Hospital, Glasgow, UK
hrp0089p1-p031
Bone Mineral Density and Glycemic Control in Children and Adolescents with Type 1 Diabetes Mellitus
aPediatric Research Unit, HC Andersen Childrens Hospital, Odense University Hospital, Odense C, Denmark; bOPAC, Odense Pancreas Centre, Odense University Hospital, Odense C, Denmark; cOrthopaedic Research Unit, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense C, Denmark
hrp0089p1-p032
Is Plasma C-Type Natriuretic Peptide Level Available for Typing and Diagnosis of Skeletal Dysplasia Cases?
aEge University Faculty of Medicine, Department of Pediatrics, Izmir, Turkey; bEge University Faculty of Medicine, Department of Pediatric Endocrinology and Diabetes, Izmir, Turkey; cEge University Faculty of Medicine, Department of Pediatric Radiology, Izmir, Turkey; dEge University Faculty of Medicine, Department of Pediatric Genetics, Izmir, Turkey; eEge University Faculty of Medicine, Department of Medical Genetics, Izmir, Turkey
hrp0089p1-p034
Long-term Outcomes of Osteogenesis Imperfecta in the Bisphosphonate Era
aRoyal Children’s Hospital, Melbourne, Australia; bMurdoch Childrens Research Institute, Melbourne, Australia.
hrp0089p1-p035
Novel LRP5 Loss-of-function Mutation Causes Osteoporosis-pseudoglioma Syndrome
aCentro de Investigaciones Endocrinológicas ‘Dr. César Bergadá’ (CEDIE) CONICET- FEI-División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina; bServicio de Genética, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina; cInstitute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, Universidad Autonóma de Madrid, IdiPAZ, Madrid, Spain; dSkeletal dysplasia Multidisciplinary Unit (UMDE), Hospital Universitario La Paz, Madrid, Spain; eCIBERER, ISCIII, Madrid, Spain
hrp0089p1-p036
Hypercalcaemia after Treatment with Denosumab in Children: Bisphosphonates as an Option for Therapy and/or Prevention?
aDr. von Haunersches Children’s Hospital of the Ludwig-Maximilians-University of Munich, Department of pediatric Endocrinology, Munich, Germany; bClinicum of the Ludwig-Maximilians-University of Munic, Orthopedic Department, Munich, Germany.
hrp0089p1-p037
Disease Burden and Systemic Manifestations of HPP in Children Enrolled in the Global HPP Registry
aDepartment of Endocrinology and Diabetes, Birmingham Children’s Hospital, Birmingham, UK; bInstitute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK; cFeinberg School of Medicine, Northwestern University, Chicago, USA; dLurie Children’s Hospital of Chicago, Chicago, USA; eAlexion Pharmaceuticals, Inc., New Haven, USA; fAlexion Pharmaceuticals, Inc., Lexington, USA; gAPHP, Bicêtre Paris-Sud, University Paris Saclay, Le Kremlin Bicêtre, France; hDepartment of Pediatrics, Osaka University, Graduate School of Medicine, Suita, Osaka, Japan; iUniversity of Manitoba, Rady Faculty of Health Sciences, Max Rady College of Medicine, and Children’s Hospital Research Institute of Manitoba, Manitoba, Canada; jOrthopaedic Clinic King-Ludwig-Haus, University of Würzburg, Würzburg, Germany; kDepartment of Pediatrics, Duke University Medical Center, Durham, USA
hrp0089p1-p038